Literature DB >> 2409595

Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria.

F Zavala, J P Tam, M R Hollingdale, A H Cochrane, I Quakyi, R S Nussenzweig, V Nussenzweig.   

Abstract

Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409595     DOI: 10.1126/science.2409595

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  103 in total

1.  A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.

Authors:  Kasey A Karen; Cailin Deal; Robert J Adams; Carolyn Nielsen; Cameron Ward; Diego A Espinosa; Jane Xie; Fidel Zavala; Gary Ketner
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

Review 2.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

Review 3.  Antigenic diversity and immune evasion by malaria parasites.

Authors:  Marcelo U Ferreira; Mônica da Silva Nunes; Gerhard Wunderlich
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 4.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 5.  The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite?

Authors:  L Schofield
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

6.  PhiXing-it, displaying foreign peptides on bacteriophage ΦX174.

Authors:  Kristofer J Christakos; Janice A Chapman; Bentley A Fane; Samuel K Campos
Journal:  Virology       Date:  2015-12-03       Impact factor: 3.616

7.  Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.

Authors:  L F Fries; D M Gordon; R L Richards; J E Egan; M R Hollingdale; M Gross; C Silverman; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

8.  Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.

Authors:  Y P Shi; S E Hasnain; J B Sacci; B P Holloway; H Fujioka; N Kumar; R Wohlhueter; S L Hoffman; W E Collins; A A Lal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein.

Authors:  Y P Shi; V Udhayakumar; M P Alpers; M M Povoa; A J Oloo; T K Ruebush; A A Lal
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.

Authors:  Diego A Espinosa; Gabriel M Gutierrez; Maricarmen Rojas-López; Amy R Noe; Lirong Shi; Sze-Wah Tse; Photini Sinnis; Fidel Zavala
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.